EGFR and non-small cell lung carcinoma: It is now also the standard of care as a first-line treatment for all patients with locally advanced or metastatic EGFR-mutant NSCLC regardless of the T790M mutation status (Soria et al, 2018; Ramalingam et al, 2020).